Ironwood Pharmaceuticals PE ratio IRWD

Share price divided by earnings per share over the last twelve months, since 2020.

Today, Oct 23, 2026: 4.5×
7-year median: 14.9×
Against its 7-year history: 0th; percentile: 0 is its lowest day, 100 its highest
7-year range: 4.5× to 127×
Peer median: 12.8×

Ironwood Pharmaceuticals' PE ratio is 4.5× as of Oct 23, 2026: a share price of $3.46 against $0.77 of earnings per share over the last twelve months.

That is below its 7-year median of 14.9×, lower than on 100% of days in the last 7 years.

Over that time it ranged from 4.5× in Oct 2026 to 127× in Aug 2024.

The median for 10 large drugmakers of a similar size is 12.8×.

PE ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	4.5×	4.5×	34.9×
2025	21.3×	20.9×	23.9×
2024	105×	99.0×	127×
2023	11.0×	10.0×	13.2×
2022	13.0×	10.0×	13.0×
2021	14.9×	12.3×	17.1×
2020	16.3×	15.0×	87.4×

Against its peers

Companies in Drug Manufacturers - General nearest Ironwood Pharmaceuticals' size, closest first, today.

Company	PE ratio
IRWDIronwood Pharmaceuticals	4.5×
PBYIPuma Biotechnology	21.2×
ZVRAZevra Therapeutics	10.5×
CRMDCorMedix	3.7×
ARVNArvinas	45.6×
COLLCollegium Pharmaceutical	18.5×
ABUSArbutus Biopharma	5.4×
AMPHAmphastar Pharmaceuticals	14.8×
OMEROmeros	10.9×
PCRXPacira BioSciences	104×
ANABAnaptysbio	10.7×
Peer median	12.8×

Where Ironwood Pharmaceuticals ranks

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Ironwood Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.